SLP - Simulations Plus, Inc. Stock Analysis | Stock Taper
Logo

About Simulations Plus, Inc.

https://www.simulations-plus.com

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft.

Shawn O'Connor

CEO

Shawn O'Connor

Compensation Summary
(Year 2025)

All Other Compensation $4,397
Total Compensation $4,397
Industry Medical - Healthcare Information Services
Sector Healthcare
Went public June 18, 1997
Method of going public IPO
Full time employees 243

Split Record

Date Type Ratio
2007-10-02 Forward 2:1
2006-08-14 Forward 2:1

ETFs Holding This Stock

Ratings Snapshot

Rating : B-

Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 2
Overall Score 2

Most Recent Analyst Grades

Grade Summary

Buy 1
Overweight 1
Sector Weight 1
Market Perform 1
Neutral 1

Showing Top 5 of 5

Price Target

Target High $65
Target Low $47
Target Median $56
Target Consensus $56

Institutional Ownership

Summary

% Of Shares Owned 67.25%
Total Number Of Holders 210

Showing Top 3 of 210